Related Experiment Video

Updated: Jun 27, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

[Small interfering RNA targeting C-erbB-2 gene increases the radiosensitivity of lung adenocarcinoma cells in vitro]

Hua-Shan Shi1, De-Lian Ren, Xin-Mei Cao

  • 1Department of Immunology, Luzhou Medical College, Luzhou 646000, China.

Nan Fang Yi Ke Da Xue Xue Bao = Journal of Southern Medical University
|November 27, 2008
PubMed
Abstract

Insights

Small interfering RNA (siRNA) targeting the C-erbb-2 oncogene significantly increased lung adenocarcinoma cell apoptosis when combined with gamma-ray exposure. This suggests siRNA enhances radiosensitivity in C-erbb-2-overexpressing lung cancer cells.

Area of Science:

  • Oncology
  • Molecular Biology
  • Radiotherapy

Context:

  • Lung adenocarcinoma is a major cause of cancer-related deaths.
  • The C-erbb-2 oncogene is frequently overexpressed in certain lung cancers.
  • Radiotherapy is a standard treatment, but resistance can limit efficacy.

Purpose:

  • To evaluate the impact of small interfering RNA (siRNA) targeting the C-erbb-2 oncogene on the radiosensitivity of lung adenocarcinoma cells.
  • To determine if C-erbb-2 gene silencing can sensitize cancer cells to gamma irradiation.

Summary:

  • Small interfering RNA (siRNA) targeting C-erbb-2 mRNA was synthesized and validated for efficacy.
  • Calu-3 lung adenocarcinoma cells with C-erbb-2 overexpression were transfected with the most effective siRNA.
  • Cells were subsequently exposed to 2 Gy or 5 Gy of gamma irradiation, and apoptosis rates were measured.
  • The combination of siRNA targeting C-erbb-2 and gamma irradiation significantly increased the apoptosis rate compared to irradiation or siRNA alone.

Impact:

  • This study demonstrates that silencing the C-erbb-2 oncogene can enhance the effectiveness of radiotherapy in lung adenocarcinoma.
  • The findings suggest a potential therapeutic strategy to improve treatment outcomes for patients with C-erbb-2-overexpressing lung cancers.
  • Targeting C-erbb-2 with siRNA offers a novel approach to overcome radioresistance in lung adenocarcinoma.

More Related Videos

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

Related Concept Videos

Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
RNA Interference01:23

RNA Interference

RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...